Stock SNPX SYNAPTOGENIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Delayed Nasdaq
Other stock markets
 10:40:27 2024-07-16 EDT 		5-day change 1st Jan Change
4.46 USD +0.68% Intraday chart for Synaptogenix, Inc. -1.47% -34.77%
07-11 Maxim Upgrades Synaptogenix to Buy From Hold, Price Target is $14 MT
06-26 Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis CI

Evolution of the average Target Price on Synaptogenix, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f67cda0b0.yBsqeWrhIClC0oPCO7WQMqpOtG92IT92tDIstLLhhVw.nHlbFQXSVXwgtsatXfj_e9g61V0kSAkv-Qpk5MPZzQysShwxH5gURhXl2g~20eec0c905a0f16856cee0f3c49eec03

Analyst Recommendations on Synaptogenix, Inc.

Maxim Upgrades Synaptogenix to Buy From Hold, Price Target is $14 MT
Maxim Downgrades Synaptogenix to Hold From Buy MT
Maxim Initiates Synaptogenix at Buy with $14 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
4.43 USD
Average target price
14 USD
Spread / Average Target
+216.03%
High Price Target
14 USD
Spread / Highest target
+216.03%
Low Price Target
14 USD
Spread / Lowest Target
+216.03%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Synaptogenix, Inc.

Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SNPX Stock
  4. Consensus Synaptogenix, Inc.